Daiichi Sankyo (TYO:4568) appointed Ken Keller as Chief Commercialization Officer, effective April 1, 2027, in its bid to become a top-five global oncology company by 2035.
Keller will lead a new global commercialization unit, centralizing operations to boost efficiency and consistency under the five-year plan, according to a statement on Monday.
Keller will retain his board seat at Daiichi Sankyo and continue as chairman, president and CEO of the company's U.S. subsidiary, having joined the company in 2014 and led its global oncology business for the past five years.